BioMarin to Acquire Alesta for $275 Million, Gaining Potential First Oral Therapy for Rare Bone Disease HPP

BioMarin is buying Alesta for $275M to add ALE1, a potential first-in-class oral therapy for hypophosphatasia, expanding its rare disease pipeline.